NCT03603431View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

March 13, 2019

Study Completion Date

March 13, 2019

Conditions

Healthy Volunteer

Interventions

DRUG

MRG-110

Single ascending doses of MRG-110

DRUG

Placebo

Single doses of placebo

DRUG

MRG-110

Multiple ascending doses of MRG-110

DRUG

Placebo

Multiple doses of Placebo

Trial Locations (1)

68502

Celerion, Inc., Lincoln

All Listed Sponsors

lead

miRagen Therapeutics, Inc.

INDUSTRY

NCT03603431 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers | Biotech Hunter | Biotech Hunter